Thu, Jul 24, 2014, 4:52 AM EDT - U.S. Markets open in 4 hrs 38 mins


% | $
Click the to save as a favorite.

Amarantus Bioscience Holdings, Inc Message Board

  • solantey Feb 28, 2013 8:45 AM Flag

    Short Term Target Price: .45

    .45 may be on the low side.

    Considering the potential impact of the "Human Brain Mapping Project", the investment to date of approximately $35,000,000 in developing the patented MANF technology, and the value attached to Amarantus Diagnostics, and the fact that the GDNF technology sold for $265,000,000 I would attach a current value to Amarantus Bioscience in the $100,000,000 range or about .45/share.

    A joint venture or "big pharma" partnership announcement and the resulting short squeeze could take it much higher but it would probably settle in the .45-.50 range.

    p.s. I'm being very conservative in my approach.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.148+0.002(+1.37%)Jul 23 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Facebook, Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT
Xilinx Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT